Validation of a novel ELISA-based VASP whole blood assay to measure P2Y12-ADP receptor activity

Thrombosis and Haemostasis

Volumn 104, Issue 2, 2010, Pages 410-411

  Barragan, Paul ^a   Paganelli, Franck ^b   Camoin Jau, Laurence ^c,d   Bourguet, Nicolas ^e   Boulay Moine, Daniele ^e   Moulard, Maxime ^e   Bonello, Laurent ^b,c  

^a Clinique les Fleurs   (France)

^b HÔPITAL NORD   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

^d INSERM   (France)

^e BioCytex   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ASSAY; BLOOD SAMPLING; CORONARY ARTERY DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; LETTER; LOADING DRUG DOSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REPRODUCIBILITY; THROMBOCYTE ACTIVATION; VALIDATION PROCESS;

EID: 77955453896     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-02-0086     Document Type: Letter

References (15)

1. Schömig A, Neumann FJ, Kastrati A, et al. A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089. (Pubitemid 26120185)
2. CURE Investigators. Clopidogrel in Unstable angina to prevent Recurrent Events trial Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
3. Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171-3175.
4. Bonello L, Paganelli F, Arpin-Bornet M, et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007; 5: 1630-1636. (Pubitemid 47091403)
5. Morel O, Viellard C, Faure A, et al. Platelet responsiveness to clopidogrel in patients with coronary syndrome. Comparison of platelet aggregation induced by ADP and flow cytometric analysis of intraplatelet VASP phosphorylation. Ann Cardiol Angiol 2007; 56: 21-29.
6. Schwarz UR, Geiger J, Walter U et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets - definition and detection of ticlopidine/ clopidogrel effects. Thromb Haemost 1999; 82: 1145-1152. (Pubitemid 29419734)
7. Geiger J, Teichmann L, Grossmann R et al. Monitoring of clopidogrel action: comparison of methods. Clin Chem 2005; 51: 957-965. (Pubitemid 40740875)
8. Aleil B, Ravanat C, Cazenave JP, et al. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with thrombotic cardiovascular diseases. J Thromb Haemost 2005; 3: 85-92. (Pubitemid 41647119)
9. Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295-302 (Pubitemid 36792384)
10. Blindt R, Stellbrink K, de Taeye A, et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007; 98: 1329-1334. (Pubitemid 350239106)
11. Frere C, Cuisset T, Quilici J, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843. (Pubitemid 47555077)
12. Bonello L, Camoin-Jau L, Arques S, et al. Adjusted Clopidogrel Loading Doses According to VASP Phosphorylation Index Decrease Rate of Major Adverse Cardiovascular Events in Patients With Clopidogrel Resistance: A Multicentre Randomized Prospective Study. J Am Coll Cardiol 2008; 51: 1404-1411. (Pubitemid 351447314)
13. Bonello L, Camoin-Jau L, Armero S et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009; 103: 5-10.
14. TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009; 30: 1753-1763.
15. Serebruany V, Rao SV, Silva MA et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2010; 31: 227-235.